Albany, NY -- (SBWIRE) -- 03/18/2020 -- Vasomotor Symptoms Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Vasomotor Symptoms Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Vasomotor Symptoms associated with a post-menopause prevalence was 41,096,968 in 2017 in 7MM countries.
2. The United States has recorded the highest prevalent population of Hot Flashes associated with Post Menopause of 18,926,632 cases in 2017.
Key benefits of the report
1. Vasomotor Symptoms market report covers a descriptive overview and comprehensive insight of the Vasomotor Symptoms epidemiology and Vasomotor Symptoms market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Vasomotor Symptoms market report provides insights into the current and emerging therapies.
3. Vasomotor Symptoms market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Vasomotor Symptoms market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Vasomotor Symptoms market.

Request for sample pages

"Vasomotor Symptoms Market Size is increasing at a CAGR of 7%."

Hot Flashes refer to the sudden sensation of extreme heat in the upper body, particularly the face, neck, and chest. The current therapeutic landscape of Hot Flashes Associated with menopause in the US can be divided into two major categories based on the class of drug. These are Hormonal Therapies and Nonhormonal Therapy.

Hormone therapy (HT) consists of estrogen-only therapy or combined-estrogen- progestogen therapy. It is the most common form of treatment in relieving vasomotor symptoms.

A slew of potential systemic therapies is being investigated for the management of Hot Flashes Associated with post-menopause. It is anticipated that the market size of currently available therapies (both hormonal and nonhormonal) for the hot flashes associated with menopause treatment is expected to increase, owing to the launch of upcoming therapies in the forecast period [2020–2030]. Moreover, the ratio of hormonal to nonhormonal therapies prescribed for the treatment of hot flashes will decrease significantly.

It is expected that the market size of currently available therapies (both hormonal and nonhormonal) for the treatment of hot flashes associated with menopause is expected to increase, owing to the launch of upcoming therapies in the forecast period [2020–2030]. Moreover, the ratio of hormonal to nonhormonal therapies prescribed for the treatment of hot flashes will decrease significantly.

The launch of the emerging therapies is expected to significantly impact Vasomotor Symptoms treatment scenario in the upcoming years:-
Drugs covered
1. Donesta
2. NT-814
3. FP-101
4. Fezolinetant
5. SJX 653
6. MT-8554
And many others

The key players in Vasomotor Symptoms market are:
1. Mithra Pharmaceuticals (Donesta Biosciences)
2. KaNDy Therapeutics
3. Fervent Pharmaceuticals
4. Astellas Pharma
5. Sojournix
6. Mitsubishi Tanabe Pharma
And many others

Table of contents
1. Key Insights
2. Vasomotor Symptoms Market Overview at a Glance
3. Executive summary
4. Organizations
5. Vasomotor Symptoms Epidemiology and Market Methodology
6. Vasomotor Symptoms associated with menopause Disease Background and Overview
7. Vasomotor Symptoms Epidemiology and Patient Population
8. Total Vasomotor Symptoms in Post-menopause Prevalent cases in 7MM
9. Country Wise Hot Flashes Associated with Post-menopause Epidemiology
9.1. United States
9.2. EU5 Countries
9.3. Germany
9.4. France
9.5. Italy
9.6. Spain
9.7. United Kingdom
9.8. Japan
10. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices
11. Unmet Needs
12. Vasomotor Symptoms Marketed drugs by class
12.1. Hormonal Therapies
12.2. Non-hormonal Therapies
12.3. Recent additions in Hormonal therapies
12.4. Bijuva: TherapeuticsMD
13. Vasomotor Symptoms Emerging Therapies
13.1. Key Cross Competition
13.2. Hormonal Based therapies
13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
13.4. Non-Hormonal Based therapies
13.5. NT-814: KaNDy Therapeutics
13.6. FP-101: Fervent Pharmaceuticals
13.7. Fezolinetant: Astellas Pharma
13.8. Other Potential therapies
13.9. SJX 653: Sojournix
13.10. MT-8554: Mitsubishi Tanabe Pharma
14. Hot Flashes 7 Major Market Analysis
15. Seven Major Market Outlook
15.1. United States Market Size
15.2. Germany
15.3. France
15.4. Italy
15.5. Spain
15.6. United Kingdom
15.7. Japan
16. Market Drivers
17. Market Barriers
18. SWOT
19. Case Studies
20. KOL Views
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight